RARγ has been previously reported as an oncogene in several cancers, including cholangiocarcinoma [33], hepatocellular carcinoma [34] and colorectal cancer [35]; however, in those cancers, the nuclear receptor RARγ was overexpressed in the cytoplasm rather than in the nucleus for unknown reasons. The gene discussed is RARG; the disease is cholangiocarcinoma.